Clinical trial
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities - a Randomized Controlled Parallel Assigned Study
NCT05104918 is registered in ClinicalTrials.gov with Scotmann Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities - a Randomized Controlled Parallel Assigned Study
- Lead sponsor
- Scotmann Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- February 28, 2022
- Completion date
- June 30, 2022
- Enrollment
- 500 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.